Abivax S.A. (ABVX)
Company Description
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France.
Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV.
It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer.
In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus.
ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
The company was incorporated in 2013 and is headquartered in Paris, France.
| Country | FR |
| IPO Date | Oct 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Marc M. P. de Garidel |
Contact Details
Address: 5, rue de la Baume Paris, FR | |
| Website | https://www.abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001956827 |
| CUSIP Number | 00370M103 |
| ISIN Number | US00370M1036 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer & Director |
| Didier Blondel | EVice President, Chief Financial Officer & Board Secretary |
| Chris Rabbat Ph.D. | Vice President & Global Head of Medical Affairs |
| Didier Scherrer Ph.D. | Chief Scientific Officer |
| Hema Keshava | Senior Vice President of Finance |
| Ida Hatoum | Chief People & Compliance Officer |
| Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing |
| Kevin Shan Ph.D. | Vice President & Global Head of Biometrics |
| Patrick Malloy | Senior Vice President of Investor Relations |
| Pierre Courteille M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jul 31, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jul 24, 2025 | 424B5 | Filing |
| Jul 24, 2025 | 6-K | Filing |
| Jul 24, 2025 | FWP | Filing |
| Jul 23, 2025 | FWP | Filing |
| Jul 23, 2025 | 424B5 | Filing |
| Jul 23, 2025 | F-3ASR | Filing |
| Jul 22, 2025 | 6-K | Filing |
| Jun 11, 2025 | 6-K | Filing |